Literature DB >> 6127086

Effect of a new potent H2-blocker, 3-[[[2-(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats.

M Takeda, T Takagi, Y Yashima, H Maeno.   

Abstract

A new H2-blocker, 3-[[[2-[(diaminoethylene)amino]-4-thiazolyl]ethyl]thio]-N2-sulfamoyl propionamidine (YM 11170) inhibited gastric secretion of both acid and pepsin, when given intraduodenally to pylorus-ligated rats. The effectiveness of YM-11170 in the inhibition of acid output was 50 times as potent as that of cimetidine. The higher antisecretory activity of YM-11170 than that of 1-cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)-methyl]thio]ethyl]guanidine (cimetidine) was also demonstrated by oral or i.v. administration. The development of gastric ulcer induced by either indometacin or acetylsalicylic acid in rats was markedly suppressed by YM-11170 with higher potency than by cimetidine. In castrated and androgenized rats, the decrease in the seminal vesicle and ventral prostate weights was not observed after treatment with YM-11170. These results suggest that YM-11170 is a potent antisecretory agent without antiandrogenic activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127086

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

1.  JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.

Authors:  B Palacios; M J Montero; M A Sevilla; L S Román
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  1976 and all that!--20 years of antisecretory therapy.

Authors:  A Garner; H Fadlallah; M E Parsons
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

Review 3.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  Some studies of the action of betahistine at H1 and H2 receptors for histamine.

Authors:  P R Gater; S E Webber; G P Gui; C C Jordan; N A Hayes; J J Ashford; J C Foreman
Journal:  Agents Actions       Date:  1986-06

5.  Mechanism of action of H2-antagonists on histamine- or dimaprit-stimulated H2-receptors of spontaneously beating guinea-pig atrium.

Authors:  M J Krielaart; D M Veenstra; K J van Buuren
Journal:  Agents Actions       Date:  1990-08

6.  The binding of [3H]-tiotidine to homogenates of guinea-pig lung parenchyma.

Authors:  J C Foreman; D B Norris; T J Rising; S E Webber
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

7.  MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effect.

Authors:  R W McCallum; A N Chremos; B Kuljian; M A Tupy-Visich; P B Huber
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

8.  Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.

Authors:  C Scarpignato; R Tramacere; L Zappia
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

9.  Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.

Authors:  J L Smith; M A Gamal; A N Chremos; D Y Graham
Journal:  Dig Dis Sci       Date:  1985-04       Impact factor: 3.199

Review 10.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.